Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
New England Journal of Medicine2016Vol. 375(11), pp. 1019–1032
Citations Over TimeTop 1% of 2016 papers
Anthony L. Cunningham, Himal Lal, Martina Kovac, Roman Chlíbek, Shinn‐Jang Hwang, Javier Díez‐Domingo, Olivier Godeaux, Myron J. Levin, Janet E. McElhaney, Joan Puig‐Barberà, Carline Vanden Abeele, Timo Vesikari, Daisuke Watanabe, Toufik Zahaf, Anitta Ahonen, Eugene Athan, José Fernando Barba‐Gómez, Laura Cámpora, Ferdinandus de Looze, H. Jackson Downey, Wayne Ghesquière, Iris Gorfinkel, Tiina Korhonen, Edward Leung, Shelly McNeil, Lidia Oostvogels, Lars Rombo, Jan Smetana, Lily Yin Weckx, W W Yeo, Thomas C. Heineman
Abstract
In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).
Related Papers
- → Acute herpes zoster and postherpetic neuralgia(1999)5 cited
- → Corticosteroid treatment in the prevention of postherpetic neuralgia(1991)2 cited
- Treatment of postherpetic neuralgia with Yangxueqvfengtang(2010)
- THERAPEUTIC EFFECT OF NEUROTROPIN IN THE TREATMENT OF POSTHERPETIC NEURALGIA IN PATIENTS WITH HERPES ZOSTER(2005)
- Clinical Effect of Valacidovir Combined with Analgecine in the Treatment of Postherpetic Neuralgia(2013)